论文部分内容阅读
目的2型糖尿病存在内皮依赖性血管舒张功能(FMVD)障碍,罗格列酮治疗可显著改善FMVD。方法对22例早期2型糖尿病患者服用罗格列酮(RGZ)4mg/d,治疗4个月,治疗前后测定内皮依赖性血管舒张功能(FMVD),并监测血糖、血脂、血红蛋白的改变。结果治疗后FMVD明显改善(P<0.01),FPG、2hPG、TG、HbA1C水平下降(P<0.01)。结论短期RGZ治疗能使T2DM患者内皮细胞明显改善,其机制可能与缓解内皮细胞胰岛素抵抗和慢性炎症状态有关。
Purpose Type 2 diabetes has endothelial-dependent vasodilation (FMVD) disorders, and rosiglitazone treatment significantly improves FMVD. Methods 22 patients with early type 2 diabetes were treated with rosiglitazone (RGZ) 4 mg / d for 4 months. Endothelium-dependent vasodilatation (FMVD) was measured before and after treatment, and blood glucose, blood lipid and hemoglobin were measured. Results After treatment FMVD significantly improved (P <0.01), FPG, 2hPG, TG, HbA1C levels decreased (P <0.01). Conclusion Short-term RGZ treatment can significantly improve the endothelial cells in T2DM patients, and its mechanism may be related to the alleviation of endothelial cell insulin resistance and chronic inflammation.